Monopar Therapeutics MNPR 深 沪
已收盘 08-01 16:00:00 美东时间
40.69
-0.490
-1.19%
华盛通- 最 高41.60
- 今 开41.60
- 成交量 3.58万股
- 最 低 39.61
- 昨 收 41.18
- 总市值 2.49亿
- 52周最高 54.30
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 1.719
- 委 比 94.17%
- 总股本 611.52万
- 历史最高 240.00
- 量 比 3.24
- 振 幅 4.83%
- 历史最低 1.3695
- 每 手 1
- 风险率 14.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅199.47%！杰富瑞上调Cogent Biosciences目标价至28美元，维持"买入"评级
今日重点评级关注：杰富瑞：维持Cogent Biosciences"买入"评级，目标价从23美元升至28美元；Leerink Partners：维持Cogent Biosciences"跑赢大市"评级，目标价从16美元升至18美元
07-08 09:34
Cantor Fitzgerald Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $74
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $74.
07-08 04:27
美股大行评级 | 买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元
买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元>>
06-24 10:07
Chardan Capital Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $60
Chardan Capital analyst Keay Nakae initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $60.
06-23 18:59
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
Monopar Therapeutics Inc. and Excel Diagnostics and Nuclear Oncology Center (EDNOC) received FDA authorization for their Expanded Access Program (EAP) using investigational agents MNPR-101-Zr and MNPR-101-Lu for imaging and treating uPAR-expressing advanced solid tumors. The program is now enrolling patients at EDNOC in Houston, Texas. MNPR-101-Zr is designed for imaging, while MNPR-101-Lu is intended for therapy, targeting cancers like triple-ne...
06-11 11:00
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Monopar Therapeutics Inc. will be added to the Russell 3000® and Russell 2000® Indexes after June 27, 2025, following the annual reconstitution of the Russell U.S. Indexes. This reflects the company's growth and recognition of its ALXN1840 drug candidate for Wilson disease. The Russell Indexes are widely used by investors, representing around $10.6 trillion in assets. Membership will last one year. Monopar also has radiopharmaceutical programs fo...
06-03 11:00
Monopar Therapeutics Q1 EPS $(0.38) Beats $(0.68) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.68) by 44.12 percent. This is a 25.49 percent increase over losses of $(0.51) per share
05-13 21:51
Jones Trading Downgrades Monopar Therapeutics to Hold
Jones Trading analyst Justin Walsh downgrades Monopar Therapeutics (NASDAQ:MNPR) from Buy to Hold.
04-02 19:54
美股大行评级 | 潜在涨幅4159%！HC Wainwright & Co.上调BiomX目标价至21美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1114111385008877568.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BiomX(PHGE)"买入"评级，目标价从2美元升至21美元</p> <p>• HC Wainwright & Co.：维持Unicycive Therapeu
04-02 09:42
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Impact BioMedical (AMEX:IBO) stock increased by 98.1% to $4.12 during ...
03-22 01:05
